At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 220 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Placebo, Dexamethasone, and 2 other interventions for Multiple Myeloma. Completed, enrolled 220 participants across 57 sites in 15 countries.
Detailed Summary
The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doctors will collect information about the effectiveness and side effects of this therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesBrazil, Canada, France, Germany, Greece, Italy, Mexico, Netherlands, Poland, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJul 2012
Primary CompletionJul 2014
TodayJul 2026
First PostedMay 18, 2012
Enrollment StartJul 1, 2012
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.1 years ago
Interventions
Placebodrug
Administered IV
Dexamethasonedrug
Administered orally
Bortezomibdrug
Administered SQ
Tabalumabbiological
Administered IV